Education
About Us
Working with TipRanks
Follow Us
Anika Therapeutics (ANIK)
NASDAQ:ANIK
ANIK Stock Chart & Stats
$9.75
$0.27(1.72%)
At close: 4:00 PM EST
$9.75
$0.27(1.72%)
Day’s Range― - ―
52-Week Range$7.87 - $17.21
Previous CloseN/A
Volume22.29K
Average Volume (3M)174.95K
Market Cap
$189.22M
Enterprise Value$170.34M
Total Cash (Recent Filing)$57.48M
Total Debt (Recent Filing)$24.20M
Price to Earnings (P/E)―
Beta0.84
Next Earnings
May 07, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.31
Shares Outstanding13,400,751
10 Day Avg. Volume181,118
30 Day Avg. Volume174,954
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)0.96
Price to Sales (P/S)1.22
P/FCF Ratio31.59
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue1.51
Enterprise Value/Gross Profit2.67
Enterprise Value/Ebitda-41.66
Forecast
1Y Price Target
$17.50Price Target Upside79.49% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.49
Revenue Forecast (FY)$116.35M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthA sizable cash position with no debt and consistent operating and free cash flow generation provides flexibility to invest selectively and withstand headwinds while leadership transition maintains guidance continuity.
Commercial ExpansionCommercial channel growth supported overall revenue performance and management's outlook signals continued expansion of the commercial channel, which can drive further top-line improvement.
Profitability And MarginsStronger revenue and improved gross margins produced profitability that surpassed expectations, supporting a path to modest positive adjusted EBITDA margins as operational efficiency improves.
Bears Say
Limited External Growth StrategyNew CEO's stated preference to prioritize optimization of current assets over pursuing external growth reduces potential upside from acquisitions and limits strategic avenues for rapid scale.
OEM Channel WeaknessWeakness in the OEM channel acted as a drag on overall revenue performance, increasing reliance on the commercial channel and exposing the stock to OEM demand swings.
Anika Therapeutics News
ANIK FAQ
What was Anika Therapeutics’s price range in the past 12 months?
Anika Therapeutics lowest stock price was $7.87 and its highest was $17.21 in the past 12 months.
What is Anika Therapeutics’s market cap?
Anika Therapeutics’s market cap is $189.22M.
When is Anika Therapeutics’s upcoming earnings report date?
Anika Therapeutics’s upcoming earnings report date is May 07, 2026 which is in 59 days.
How were Anika Therapeutics’s earnings last quarter?
Anika Therapeutics released its earnings results on Feb 26, 2026. The company reported $0.31 earnings per share for the quarter, beating the consensus estimate of -$0.125 by $0.435.
Is Anika Therapeutics overvalued?
According to Wall Street analysts Anika Therapeutics’s price is currently Undervalued.
Does Anika Therapeutics pay dividends?
Anika Therapeutics does not currently pay dividends.
What is Anika Therapeutics’s EPS estimate?
Anika Therapeutics’s EPS estimate is -0.07.
How many shares outstanding does Anika Therapeutics have?
Anika Therapeutics has 13,400,751 shares outstanding.
What happened to Anika Therapeutics’s price movement after its last earnings report?
Anika Therapeutics reported an EPS of $0.31 in its last earnings report, beating expectations of -$0.125. Following the earnings report the stock price went up 16.91%.
Which hedge fund is a major shareholder of Anika Therapeutics?
Currently, no hedge funds are holding shares in ANIK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Anika Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.50 (79.49% Upside)
$17.50 (79.49% Upside)
Blogger Sentiment
Bullish
ANIK Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 33.1K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.14%
12-Months-Change
Fundamentals
Return on Equity
-8.73%
Trailing 12-Months
Asset Growth
-18.14%
Trailing 12-Months
Company Description
Anika Therapeutics
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
ANIK Company Deck
ANIK Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call reported meaningful commercial momentum (commercial channel +22% in Q4, +15% full year), strong early traction for Integrity (revenue doubled to ~$6M; procedural growth), Q4 margin expansion (63% GAAP) and improved cash flow and adjusted EBITDA that exceeded expectations. Offsetting these positives were continued OEM pricing headwinds (OEM revenue down 12% in Q4 and 17% for the year), a Hyalofast Phase III shortfall and an FDA deficiency letter that introduce regulatory uncertainty, plus full-year revenue decline of 6% and margin pressure for the year. Management provided constructive 2026 guidance with modest overall growth and improved profitability, and emphasized operational improvements and cost actions. On balance, the call highlights operational and commercial progress and a path to improved profitability while noting material regulatory and OEM-channel challenges that require execution.View all ANIK earnings summariesANIK Stock 12 Month Forecast
Average Price Target
$17.50
▲(79.49% Upside)
Technical Analysis
Ownership Overview
4.26% Insiders
11.26% Mutual Funds
8.84% Other Institutional Investors
64.60% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---